Emergence of the Joint Clinical Assessment in the European Union
Sweeping developments in HTA and their impact on pharmaceutical and medtech manufacturers
Navigating EU Joint Clinical Assessments and Joint Scientific Consultations From January 2025 Onward
What Do We Need to Know About Joint Clinical Assessments (JCAs)?
IPECAD Cross Comparison Challenge on Cost-Effectiveness Models in Alz Disease and Related Dementias
Improving the transparency and credibility of cost-effectiveness models for AD
Submission Requirements of Nordic HTA Organizations for Medical Technologies
A study to assess the range of medical technology requirements in Nordic health technology assessment processes
Modelling Considerations for Evaluating the Cost-Effectiveness of Biologics
Challenges in designing conceptual models for biologic therapies in eosinophilic-associated diseases
How Much Does TLV Value Rarity? A Review of Reimbursement
Determining if the rarity of conditions affected incremental cost-effectiveness ratios in Sweden
Differences and Similarities of Health Economic Evaluation for Medical Technologies by HTA Bodies
Understanding the requirements for HTA economic evaluations
HTA Processes for Medical Technologies Across the World – Are All Hurdles the Same?
We evaluated similarities and differences in Europe, North America, South America, Asia, and Oceania
Trends in the Inclusion of Patient Reported Outcomes in Oncology Clinical Trials
We studied industry-sponsored oncology clinical trials from 2013 through 2022
Equity, Diversity, Inclusion, and Belonging in Patient Centered Drug Development
Applying EDIB principles can support more equitable health outcomes.
How Do We Get Drug Labeling Based on Patient Reported Outcomes?
We must first decide, "what's the value proposition - in simple language?"
How are United States ICER'S Evidence Ratings Determined?
A systematic review of ICER'S evidence ratings for new drugs in 2020-2021
Adverse Cardiac Events in COPD Patients Treated with Inhaled Bronchodilators
Evaluation of cardiovascular safety endpoints related to the use of aclidinium
Effects of Continuous Use of Antidepressants on Dementia
A target trial emulation
Informing Gestational Age in Pregnancy Research without Clinical Estimates
Providing estimates of gestational age at birth when clinical estimates of gestational age are not available
Tailoring Cost-Effectiveness Modeling Methodologies for Multiple Sclerosis
Designing and conducting studies that explicitly account for the eventual requirements of MS
Causal Inference Methods for Real-World Evidence
Please join Xabier Garcia de Albeniz for this recorded 30-minute workshop
Real-World Evidence You Need, When You Need It
Utilizing available data sources to demonstrate product value
Incorporating Real-World Evidence Into Your Product Development
See how RTI Health Solutions can partner with you to make the most of your real-world evidence when generating evidence for your drug or medical device development.
Get the Most Out of Your Registry Data
A case study of exploratory analyses
Using Real-World Evidence for Comparative Safety Studies
Generating valid RWE requires thoroughly understanding underlying real-world data
2020 FDA Patient-Reported Outcomes Guidance Draft
Development, evaluation, and regulatory review of clinical outcome assessments
Assessing the Quality of Data from Stated-Preference Surveys
Generating reliable data by ensuring respondents understand survey questions
Early Dialog with NICE and EUnetHTA
A UK perspective in a politically uncertain ERA
Antidepressant Drug Utilization Study
Describing the use of antidepressants in Europe and the characteristics of adult users
Assigning Treatment Strategy Using Real-World Data
When using observational data, quantifying the effect of treatment strategies that are sustained over time is not straightforward
Identifying Psychosis in Patients with Dementia
Assessing antipsychotics' mortality risk can be challenging in automated healthcare databases
Coding Variations Hinder Vaccine Efficacy and Safety Research
Researchers should evaluate accuracy of real-world data to be included in studies
Including Carer Utility Values in HTAs
A study of NICE appraisals in the EU
Best Practices for Interacting with ICER
Key changes in the last 10 years
Understanding Treatment Trends for Chronic Lymphocytic Leukemia
A retrospective cohort study
A Global Review of Quality-of-Life Impact
Atopic dermatitis in children
HTA and Reimbursement Considerations for Orphan Drugs in European Markets
Recommendations to manufacturers on evidence sources and techniques
Methods for Avoidance of Selection Bias
Adjusting for confounding in a colonoscopy screening study
Identifying a Drug's Safety Profile
Antiepileptic drugs in pregnancy: pregnancy duration, birth weight, length, and head circumference
Determining Effectiveness of Risk-Minimization Measures
Evaluating the effectiveness of implementation of EMA recommendations
Identifying an Appropriate Drug for Comparative Safety Research
Antiepileptic drugs in pregnancy
Longitudinal Modeling Approaches to Assess Association Between Two Clinical Outcomes Assessments
Robust analysis approaches, such as the joint MMRM